Neurotrope Stock Price, News & Analysis (NASDAQ:NTRP)

$8.16 0.61 (8.08 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$8.16
Today's Range$7.52 - $8.20
52-Week Range$3.40 - $29.00
Volume79,388 shs
Average Volume32,637 shs
Market Capitalization$59.61 million
P/E RatioN/A
Dividend YieldN/A

About Neurotrope (NASDAQ:NTRP)

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Software


Debt-to-Equity RatioN/A
Current Ratio11.49%
Quick Ratio11.49%


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.48 per share
Price / Book2.34


Trailing EPSN/A
Net Income$-12,920,000.00
Net MarginsN/A
Return on Equity-79.44%
Return on Assets-72.29%


Outstanding Shares7,900,000

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) announced its earnings results on Friday, August, 14th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.03. View Neurotrope's Earnings History.

Where is Neurotrope's stock going? Where will Neurotrope's stock price be in 2017?

1 analysts have issued 12 month price targets for Neurotrope's stock. Their predictions range from $31.00 to $31.00. On average, they anticipate Neurotrope's stock price to reach $31.00 in the next twelve months. View Analyst Ratings for Neurotrope.

Who are some of Neurotrope's key competitors?

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:

  • Joshua N. Silverman, Chairman of the Board (Age 46)
  • Daniel L Alkon M.D., President, Chief Scientific Officer (Age 73)
  • Susanne Wilke Ph.D., Chief Executive Officer, Director (Age 53)
  • William S. Singer, Vice Chairman of the Board (Age 74)
  • Robert Weinstein, Chief Financial Officer, Executive Vice President
  • Paula T. Trzepacz, Executive Vice President and Chief Medical Officer
  • Bruce T. Bernstein, Director
  • Kenneth J. Gorelick, Director
  • Andrew D. Perlman, Director
  • Shana Phares, Director

Who owns Neurotrope stock?

Neurotrope's stock is owned by many different of retail and institutional investors. Top institutional investors include Cannell Peter B & Co. Inc. (1.91%) and First Republic Investment Management Inc. (0.76%). Company insiders that own Neurotrope stock include Bruce Bernstein and Kenneth J Gorelick. View Institutional Ownership Trends for Neurotrope.

Who bought Neurotrope stock? Who is buying Neurotrope stock?

Neurotrope's stock was bought by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc. and Cannell Peter B & Co. Inc.. Company insiders that have bought Neurotrope stock in the last two years include Bruce Bernstein and Kenneth J Gorelick. View Insider Buying and Selling for Neurotrope.

How do I buy Neurotrope stock?

Shares of Neurotrope can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of Neurotrope stock can currently be purchased for approximately $8.16.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $59.61 million. Neurotrope employs 5 workers across the globe.

How can I contact Neurotrope?

Neurotrope's mailing address is 205 EAST 42ND STREET 17TH FLOOR, NEW YORK NY, 10017. The company can be reached via phone at 973-242-0005 or via email at [email protected]

MarketBeat Community Rating for Neurotrope (NTRP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurotrope (NASDAQ:NTRP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score:
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.00$31.00$31.00$31.00
Price Target Upside: 344.76% upside344.76% upside344.76% upside344.76% upside

Neurotrope (NASDAQ:NTRP) Consensus Price Target History

Price Target History for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ:NTRP) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2017AegisReiterated RatingBuy$31.00N/AView Rating Details
(Data available from 12/16/2015 forward)


Neurotrope (NASDAQ:NTRP) Earnings History and Estimates Chart

Earnings by Quarter for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ NTRP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2015Q2 2015($0.08)($0.11)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.10)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Neurotrope (NASDAQ:NTRP) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Neurotrope (NASDAQ:NTRP)

No dividend announcements for this company have been tracked by

Insider Trades

Neurotrope (NASDAQ NTRP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.45%
Institutional Ownership Percentage: 12.93%
Insider Trades by Quarter for Neurotrope (NASDAQ:NTRP)
Insider Trades by Quarter for Neurotrope (NASDAQ:NTRP)

Neurotrope (NASDAQ NTRP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Bruce BernsteinDirectorBuy50,000$0.28$14,000.00View SEC Filing  
11/23/2016Kenneth J GorelickDirectorBuy5,000$0.29$1,450.00View SEC Filing  
8/26/2016Kenneth J GorelickDirectorBuy5,000$0.41$2,050.00View SEC Filing  
11/23/2015James GottliebDirectorBuy10,000$0.59$5,900.00View SEC Filing  
(Data available from 1/1/2013 forward)


Neurotrope (NASDAQ NTRP) News Headlines

No headlines for this company have been tracked by

SEC Filings

Neurotrope (NASDAQ:NTRP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Neurotrope (NASDAQ NTRP) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.